Nakano Y , Oubel E , Brag J , Doreille A , Lucidarme O . Affiliations:  Median Technologies, Valbonne, France.  Hopital La Pitie Salpetriere, Paris, France.
NASH is a growing contributor to chronic liver disease and already represents the second highest cause of hepatocellular carcinoma in the United States. Current diagnosis and severity assessment typically relies on histopathological analysis from biopsy samples. With novel NASH therapies under development there is a need for reliable non-invasive assessment of disease progression. The aim of the study is to demonstrate the feasibility of using routine CT imaging protocols, combined with big data processing for extracting radiological signatures, for assessing disease progression in NASH patients. Poster presentation at: The NASH Biomarker Workshop 2017, May 5-6, 2017, Washington DC, USA